KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer

Prabhakar Pitta Venkata(The University of Texas Health Science Center at San Antonio), Gangadhara R. Sareddy(The University of Texas Health Science Center at San Antonio)
Cancer Letters
October 19, 2021
10.1016/j.canlet.2021.10.019
Cited by 19

Related Papers

Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma
|Scientific Reports|2016|71
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer
|Oncotarget|2017|43
Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer
|Cancer Letters|2023|18
Reticulocalbin 3 Is a Novel Mediator of Glioblastoma Progression
|Cancers|2023|5